A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate
Recently, a prognostic index including six risk factors (RFs) (unfavourable Eastern Cooperative Oncology Group performance status [ECOG PS], presence of liver metastases, short response to luteinizing hormone-releasing hormone [LHRH] agonists/antagonists, low albumin, increased alkaline phosphatase...
Gespeichert in:
| Veröffentlicht in: | Canadian Urological Association journal 2018-02, Vol.12 (2), p.E47-52 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 52 |
|---|---|
| container_issue | 2 |
| container_start_page | E47 |
| container_title | Canadian Urological Association journal |
| container_volume | 12 |
| creator | Khalaf, Daniel Joseph Avilés, Claudia M Azad, Arun A Sunderland, Katherine Todenhöfer, Tilman Eigl, Berhard J Finch, Daygen Le, Lyly Atwell, Andrew Keith, Bruce Kollmannsberger, Christian Chi, Kim N |
| description | Recently, a prognostic index including six risk factors (RFs) (unfavourable Eastern Cooperative Oncology Group performance status [ECOG PS], presence of liver metastases, short response to luteinizing hormone-releasing hormone [LHRH] agonists/antagonists, low albumin, increased alkaline phosphatase [ALP] and lactate dehydrogenase [LDH]) was developed from the COU-AA-301 trial in post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate. Our primary objective was to evaluate this model in a cohort of chemotherapy-naive mCRPC patients receiving abiraterone.
We identified 197 chemotherapy-naive patients who received abiraterone at six BC Cancer Agency centres and who had complete information on all six RFs. Study endpoints were prostate-specific antigen (PSA) response rate (RR), time to PSA progression, time on treatment, and overall survival (OS). PSA RR and survival outcomes were compared using Χ
test and log-rank test. Multivariable Cox proportional hazard analysis was performed to identify RFs independently associated with OS.
Patients were classified into good (0-1 RFs), intermediate (2-3 RFs), and poor (4-6 RFs) prognostic groups (33%, 52%, and 15%, respectively). For good-, intermediate-, and poor-risk patients, PSA RR (≥50% decline) was 60% vs. 42% vs. 40% (p=0.05); median time to PSA progression was 7.3 vs. 5.3 vs. 5.0 months (p=0.02); and median OS was 29.4 vs. 13.8 vs. 8.7 months (p |
| doi_str_mv | 10.5489/cuaj.4600 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5937410</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A532656158</galeid><sourcerecordid>A532656158</sourcerecordid><originalsourceid>FETCH-LOGICAL-c604t-57f7e93cafb2332e81337c0d00ace3e7e1aa8af4587ef2061f2203b0dd5289093</originalsourceid><addsrcrecordid>eNptks2KFDEQgBtR3HX14AtIUBA99Jh0-vciDIs_C4se1HOoSVems6ST3iS9Ou_jg5pm1mUGhhw6VH31pamqLHvJ6Koq2-6DnOFmVdaUPsrOWVfQnBWsfLzcGcvrsqFn2bMQbiitU6R5mp0VHW9ZWdXn2d81mbzbWheilmR0PRqinCcheoha7bTdEmm01RIMcXOUbsRAtCVywNHFAT1Mu9yCvkMyYoQQYRFJ2AuczT0GnaI2Lg8taUxZK9GTKQFoYyDRYwr35LeOA4GNTpXonUUCEpeC59kTBSbgi_vvRfbr86efl1_z6-9fri7X17msaRnzqlENdlyC2hScF9gyzhtJe0qTh2ODDKAFVVZtg6pIzVBFQfmG9n1VtB3t-EX2ce-d5s2IvUw_58GIyesR_E440OI4Y_Ugtu5OVB1vSkaT4N29wLvbGUMUow4SjQGLbg6CdR1PU6hqntA3e3QLBoW2yiWjXHCxrniRGFa1iXp9gpKTvhWH0OoElE6Po5apj0qn-JH1_VFBYiL-iVuYQxBXP74ds28P2AHBxCE4My-zDSelMo05eFQPfWNULGsqljUVy5om9tVhox_I_3vJ_wFNTuWz</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1993006563</pqid></control><display><type>article</type><title>A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Khalaf, Daniel Joseph ; Avilés, Claudia M ; Azad, Arun A ; Sunderland, Katherine ; Todenhöfer, Tilman ; Eigl, Berhard J ; Finch, Daygen ; Le, Lyly ; Atwell, Andrew ; Keith, Bruce ; Kollmannsberger, Christian ; Chi, Kim N</creator><creatorcontrib>Khalaf, Daniel Joseph ; Avilés, Claudia M ; Azad, Arun A ; Sunderland, Katherine ; Todenhöfer, Tilman ; Eigl, Berhard J ; Finch, Daygen ; Le, Lyly ; Atwell, Andrew ; Keith, Bruce ; Kollmannsberger, Christian ; Chi, Kim N</creatorcontrib><description>Recently, a prognostic index including six risk factors (RFs) (unfavourable Eastern Cooperative Oncology Group performance status [ECOG PS], presence of liver metastases, short response to luteinizing hormone-releasing hormone [LHRH] agonists/antagonists, low albumin, increased alkaline phosphatase [ALP] and lactate dehydrogenase [LDH]) was developed from the COU-AA-301 trial in post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate. Our primary objective was to evaluate this model in a cohort of chemotherapy-naive mCRPC patients receiving abiraterone.
We identified 197 chemotherapy-naive patients who received abiraterone at six BC Cancer Agency centres and who had complete information on all six RFs. Study endpoints were prostate-specific antigen (PSA) response rate (RR), time to PSA progression, time on treatment, and overall survival (OS). PSA RR and survival outcomes were compared using Χ
test and log-rank test. Multivariable Cox proportional hazard analysis was performed to identify RFs independently associated with OS.
Patients were classified into good (0-1 RFs), intermediate (2-3 RFs), and poor (4-6 RFs) prognostic groups (33%, 52%, and 15%, respectively). For good-, intermediate-, and poor-risk patients, PSA RR (≥50% decline) was 60% vs. 42% vs. 40% (p=0.05); median time to PSA progression was 7.3 vs. 5.3 vs. 5.0 months (p=0.02); and median OS was 29.4 vs. 13.8 vs. 8.7 months (p<0.0001).
The six-factor prognostic index model stratifies clinical outcomes in chemotherapy-naive mCRPC patients treated with abiraterone. Identifying patients at risk of poor outcome is important for informing clinical practice and clinical trial design.</description><identifier>ISSN: 1911-6470</identifier><identifier>EISSN: 1920-1214</identifier><identifier>DOI: 10.5489/cuaj.4600</identifier><identifier>PMID: 29381456</identifier><language>eng</language><publisher>Canada: Canadian Urological Association</publisher><subject>Cancer patients ; Care and treatment ; Original Research ; Patient outcomes ; Prostate cancer</subject><ispartof>Canadian Urological Association journal, 2018-02, Vol.12 (2), p.E47-52</ispartof><rights>COPYRIGHT 2018 Canadian Urological Association</rights><rights>Copyright: © 2018 Canadian Urological Association or its licensors 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c604t-57f7e93cafb2332e81337c0d00ace3e7e1aa8af4587ef2061f2203b0dd5289093</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937410/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937410/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29381456$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Khalaf, Daniel Joseph</creatorcontrib><creatorcontrib>Avilés, Claudia M</creatorcontrib><creatorcontrib>Azad, Arun A</creatorcontrib><creatorcontrib>Sunderland, Katherine</creatorcontrib><creatorcontrib>Todenhöfer, Tilman</creatorcontrib><creatorcontrib>Eigl, Berhard J</creatorcontrib><creatorcontrib>Finch, Daygen</creatorcontrib><creatorcontrib>Le, Lyly</creatorcontrib><creatorcontrib>Atwell, Andrew</creatorcontrib><creatorcontrib>Keith, Bruce</creatorcontrib><creatorcontrib>Kollmannsberger, Christian</creatorcontrib><creatorcontrib>Chi, Kim N</creatorcontrib><title>A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate</title><title>Canadian Urological Association journal</title><addtitle>Can Urol Assoc J</addtitle><description>Recently, a prognostic index including six risk factors (RFs) (unfavourable Eastern Cooperative Oncology Group performance status [ECOG PS], presence of liver metastases, short response to luteinizing hormone-releasing hormone [LHRH] agonists/antagonists, low albumin, increased alkaline phosphatase [ALP] and lactate dehydrogenase [LDH]) was developed from the COU-AA-301 trial in post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate. Our primary objective was to evaluate this model in a cohort of chemotherapy-naive mCRPC patients receiving abiraterone.
We identified 197 chemotherapy-naive patients who received abiraterone at six BC Cancer Agency centres and who had complete information on all six RFs. Study endpoints were prostate-specific antigen (PSA) response rate (RR), time to PSA progression, time on treatment, and overall survival (OS). PSA RR and survival outcomes were compared using Χ
test and log-rank test. Multivariable Cox proportional hazard analysis was performed to identify RFs independently associated with OS.
Patients were classified into good (0-1 RFs), intermediate (2-3 RFs), and poor (4-6 RFs) prognostic groups (33%, 52%, and 15%, respectively). For good-, intermediate-, and poor-risk patients, PSA RR (≥50% decline) was 60% vs. 42% vs. 40% (p=0.05); median time to PSA progression was 7.3 vs. 5.3 vs. 5.0 months (p=0.02); and median OS was 29.4 vs. 13.8 vs. 8.7 months (p<0.0001).
The six-factor prognostic index model stratifies clinical outcomes in chemotherapy-naive mCRPC patients treated with abiraterone. Identifying patients at risk of poor outcome is important for informing clinical practice and clinical trial design.</description><subject>Cancer patients</subject><subject>Care and treatment</subject><subject>Original Research</subject><subject>Patient outcomes</subject><subject>Prostate cancer</subject><issn>1911-6470</issn><issn>1920-1214</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNptks2KFDEQgBtR3HX14AtIUBA99Jh0-vciDIs_C4se1HOoSVems6ST3iS9Ou_jg5pm1mUGhhw6VH31pamqLHvJ6Koq2-6DnOFmVdaUPsrOWVfQnBWsfLzcGcvrsqFn2bMQbiitU6R5mp0VHW9ZWdXn2d81mbzbWheilmR0PRqinCcheoha7bTdEmm01RIMcXOUbsRAtCVywNHFAT1Mu9yCvkMyYoQQYRFJ2AuczT0GnaI2Lg8taUxZK9GTKQFoYyDRYwr35LeOA4GNTpXonUUCEpeC59kTBSbgi_vvRfbr86efl1_z6-9fri7X17msaRnzqlENdlyC2hScF9gyzhtJe0qTh2ODDKAFVVZtg6pIzVBFQfmG9n1VtB3t-EX2ce-d5s2IvUw_58GIyesR_E440OI4Y_Ugtu5OVB1vSkaT4N29wLvbGUMUow4SjQGLbg6CdR1PU6hqntA3e3QLBoW2yiWjXHCxrniRGFa1iXp9gpKTvhWH0OoElE6Po5apj0qn-JH1_VFBYiL-iVuYQxBXP74ds28P2AHBxCE4My-zDSelMo05eFQPfWNULGsqljUVy5om9tVhox_I_3vJ_wFNTuWz</recordid><startdate>20180201</startdate><enddate>20180201</enddate><creator>Khalaf, Daniel Joseph</creator><creator>Avilés, Claudia M</creator><creator>Azad, Arun A</creator><creator>Sunderland, Katherine</creator><creator>Todenhöfer, Tilman</creator><creator>Eigl, Berhard J</creator><creator>Finch, Daygen</creator><creator>Le, Lyly</creator><creator>Atwell, Andrew</creator><creator>Keith, Bruce</creator><creator>Kollmannsberger, Christian</creator><creator>Chi, Kim N</creator><general>Canadian Urological Association</general><general>Canadian Medical Association</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISN</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180201</creationdate><title>A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate</title><author>Khalaf, Daniel Joseph ; Avilés, Claudia M ; Azad, Arun A ; Sunderland, Katherine ; Todenhöfer, Tilman ; Eigl, Berhard J ; Finch, Daygen ; Le, Lyly ; Atwell, Andrew ; Keith, Bruce ; Kollmannsberger, Christian ; Chi, Kim N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c604t-57f7e93cafb2332e81337c0d00ace3e7e1aa8af4587ef2061f2203b0dd5289093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Cancer patients</topic><topic>Care and treatment</topic><topic>Original Research</topic><topic>Patient outcomes</topic><topic>Prostate cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Khalaf, Daniel Joseph</creatorcontrib><creatorcontrib>Avilés, Claudia M</creatorcontrib><creatorcontrib>Azad, Arun A</creatorcontrib><creatorcontrib>Sunderland, Katherine</creatorcontrib><creatorcontrib>Todenhöfer, Tilman</creatorcontrib><creatorcontrib>Eigl, Berhard J</creatorcontrib><creatorcontrib>Finch, Daygen</creatorcontrib><creatorcontrib>Le, Lyly</creatorcontrib><creatorcontrib>Atwell, Andrew</creatorcontrib><creatorcontrib>Keith, Bruce</creatorcontrib><creatorcontrib>Kollmannsberger, Christian</creatorcontrib><creatorcontrib>Chi, Kim N</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Canada</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Canadian Urological Association journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Khalaf, Daniel Joseph</au><au>Avilés, Claudia M</au><au>Azad, Arun A</au><au>Sunderland, Katherine</au><au>Todenhöfer, Tilman</au><au>Eigl, Berhard J</au><au>Finch, Daygen</au><au>Le, Lyly</au><au>Atwell, Andrew</au><au>Keith, Bruce</au><au>Kollmannsberger, Christian</au><au>Chi, Kim N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate</atitle><jtitle>Canadian Urological Association journal</jtitle><addtitle>Can Urol Assoc J</addtitle><date>2018-02-01</date><risdate>2018</risdate><volume>12</volume><issue>2</issue><spage>E47</spage><epage>52</epage><pages>E47-52</pages><issn>1911-6470</issn><eissn>1920-1214</eissn><abstract>Recently, a prognostic index including six risk factors (RFs) (unfavourable Eastern Cooperative Oncology Group performance status [ECOG PS], presence of liver metastases, short response to luteinizing hormone-releasing hormone [LHRH] agonists/antagonists, low albumin, increased alkaline phosphatase [ALP] and lactate dehydrogenase [LDH]) was developed from the COU-AA-301 trial in post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate. Our primary objective was to evaluate this model in a cohort of chemotherapy-naive mCRPC patients receiving abiraterone.
We identified 197 chemotherapy-naive patients who received abiraterone at six BC Cancer Agency centres and who had complete information on all six RFs. Study endpoints were prostate-specific antigen (PSA) response rate (RR), time to PSA progression, time on treatment, and overall survival (OS). PSA RR and survival outcomes were compared using Χ
test and log-rank test. Multivariable Cox proportional hazard analysis was performed to identify RFs independently associated with OS.
Patients were classified into good (0-1 RFs), intermediate (2-3 RFs), and poor (4-6 RFs) prognostic groups (33%, 52%, and 15%, respectively). For good-, intermediate-, and poor-risk patients, PSA RR (≥50% decline) was 60% vs. 42% vs. 40% (p=0.05); median time to PSA progression was 7.3 vs. 5.3 vs. 5.0 months (p=0.02); and median OS was 29.4 vs. 13.8 vs. 8.7 months (p<0.0001).
The six-factor prognostic index model stratifies clinical outcomes in chemotherapy-naive mCRPC patients treated with abiraterone. Identifying patients at risk of poor outcome is important for informing clinical practice and clinical trial design.</abstract><cop>Canada</cop><pub>Canadian Urological Association</pub><pmid>29381456</pmid><doi>10.5489/cuaj.4600</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1911-6470 |
| ispartof | Canadian Urological Association journal, 2018-02, Vol.12 (2), p.E47-52 |
| issn | 1911-6470 1920-1214 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5937410 |
| source | EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Cancer patients Care and treatment Original Research Patient outcomes Prostate cancer |
| title | A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T23%3A51%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20prognostic%20model%20for%20stratifying%20clinical%20outcomes%20in%20chemotherapy-naive%20metastatic%20castration-resistant%20prostate%20cancer%20patients%20treated%20with%20abiraterone%20acetate&rft.jtitle=Canadian%20Urological%20Association%20journal&rft.au=Khalaf,%20Daniel%20Joseph&rft.date=2018-02-01&rft.volume=12&rft.issue=2&rft.spage=E47&rft.epage=52&rft.pages=E47-52&rft.issn=1911-6470&rft.eissn=1920-1214&rft_id=info:doi/10.5489/cuaj.4600&rft_dat=%3Cgale_pubme%3EA532656158%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1993006563&rft_id=info:pmid/29381456&rft_galeid=A532656158&rfr_iscdi=true |